Randhawa Simrat exercised Options covering 23,124 Dianthus Therapeutics shares across three transactions on 2026-09-01, with exercise prices from $17.88 to $22.07 per share. The post-transaction balances distinguish Simrat’s remaining 4,000 shares from 87,500 derivative securities, giving investors the reported ownership position after the transactions.
Key Highlights
- Randhawa Simrat is Dianthus Therapeutics’ executive vice president and head of research and development.
- Simrat owned 27,124 shares after exercising the options and 4,000 shares after selling 23,124 shares.
- Simrat held 87,500 derivative securities after exercises recorded at $0 per share.
Dianthus Therapeutics, Inc. /DE/ (NASDAQ: DNTH) executive vice president and head of Research and Development Randhawa Simrat exercised options covering 23,124 shares in three transactions on 1 September 2026. The exercise prices ranged from $17.88 to $22.07 per share.
Three Option Exercises Followed by Share Sales
Simrat’s option exercises used transaction code M and were recorded at $0 per share for 23,124 derivative securities. After those exercises, Simrat owned 27,124 shares. Simrat then sold 23,124 shares across three separate transactions using transaction code S, with sale prices ranging from $105.19 to $106.74 per share. Following the sales, Simrat owned 4,000 shares. Following these transactions, Simrat owned 87,500 derivative securities.
FAQs
Q: How many Dianthus Therapeutics shares did Randhawa Simrat sell?
A: Randhawa Simrat sold 23,124 Dianthus Therapeutics shares across three transactions on 1 September 2026. The sale prices ranged from $105.19 to $106.74 per share.
Q: What did Randhawa Simrat own after the Dianthus transactions?
A: Simrat owned 4,000 Dianthus Therapeutics shares after the sales. Simrat also owned 87,500 derivative securities after the option exercises, following the reported transactions on 1 September 2026.
Q: What was the exercise price for Randhawa Simrat’s options?
A: The options covered 23,124 Dianthus Therapeutics shares and carried exercise prices ranging from $17.88 to $22.07 per share across three transactions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.